Publication: Is there a relationship between fibroblast growth factor 23 and blood pressure in children with chronic kidney disease
| dc.contributor.author | ALPAY, HARİKA | |
| dc.contributor.authors | Balmukhanova A., Kabulbayev K., ALPAY H., Balmukhanova A., Kanatbayeva A. | |
| dc.date.accessioned | 2023-07-25T10:20:19Z | |
| dc.date.accessioned | 2026-01-10T19:09:19Z | |
| dc.date.available | 2023-07-25T10:20:19Z | |
| dc.date.issued | 2022-05-01 | |
| dc.description.abstract | BACKGROUND AND AIMS: Chronic kidney disease (CKD) is a complex medical and social problem worldwide due to high prevalence and mortality rates. According to the ESPN/ERA-EDTA, the prevalence of CKD stages 3–5 in children is about 55– 60 pmarp [1]. Moreover, CKD usually causes different severe complications, including pathologic changes in the cardiovascular system, which significantly affect long-term survival. Unlike many complications of CKD, hypertension can be present in the earliest stages of the disease [2]. Nowadays, there has been a scientific and practical interest in Fibroblast growth factor 23 (FGF-23) which is mostly considered as a phosphate-regulating biomarker [3]. There are some speculations that FGF-23 affects blood pressure (BP) in adults due to the impact on the renin-angiotensin-aldosterone system (RAAS) by decreasing calcitriol [4] and the direct effect of FGF-23 on sodium reabsorption, which has been demonstrated in experimental models [5]. Therefore, the aim of our study was to investigate the link between FGF-23 and BP in children with CKD. METHOD: There were 73 children with CKD stages 1–5, mean age was 9.79 ± 0.58 years. BP was determined by 3 times measurement and calculating the mean value. Received results were compared with percentile norms according to age and gender in order to divide patients into two groups: normotensive and hypertensive. FGF-23 was determined in serum by multimatrix ELISA kit (Biomedica Medizinprodukte GmbH, Austria). Statistical analysis was performed using SPSS version 26 (IBM, USA). RESULTS: In the group with normal BP the median of FGF-23 in serum was 1.8 [0.7–3.4] pmol/L. In comparison, in the group with a hypertensive level of BP median indicator of FGF-23 was 7.6 (1.98–18.5) pmol/L (P < .001). The prevalence of elevated FGF-23 in children with high BP predominates 1.6 times [95% confidence interval (95% CI): 1.2–2.1]. It is also noticed that pulse BP positively correlated with FGF-23 level in serum (r = 0.402, P < .001). CONCLUSION: Our findings confirm that FGF-23 is linked to BP in children with CKD what makes us conclude that more careful attention to children with a high level of FGF-23 is needed in relation to hypertension and as a consequence cardiovascular complications. However, more investigations should be done in order to establish a causal relationship. | |
| dc.identifier.citation | Balmukhanova A., Kabulbayev K., ALPAY H., Balmukhanova A., Kanatbayeva A., "IS THERE A RELATIONSHIP BETWEEN FIBROBLAST GROWTH FACTOR 23 AND BLOOD PRESSURE IN CHILDREN WITH CHRONIC KIDNEY DISEASE?", NEPHROLOGY DIALYSIS TRANSPLANTATION, cilt.37, 2022 | |
| dc.identifier.issn | 0931-0509 | |
| dc.identifier.uri | https://watermark.silverchair.com/gfac089_006.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA4EwggN9BgkqhkiG9w0BBwagggNuMIIDagIBADCCA2MGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMrPG5_SRrOA3YbNqiAgEQgIIDNDmuqJs1Ike-dZWWlByCHeMja-RCOINfgvRnfuyR9KVoQ5d1Mxd_wrMr27OuFSuTsLyOf2q2D8v-mcAfjaF8mHrqpvr02CQw274DXzku7zyS2ze06TYstPVQI02djN4wH7McAPwrHcej9J1yh73mnk9qVGrvyKqNafDOpfQQ4Ydx5A67CYonQFsCRDhR9FZ8Z0Z4lLJnTqBIj69qFmhDW7HZvXqGUu1sNeSzdonLpykh9rv-Y37Pcbxm857IK_FElEl2ce17W1TzkdIZS7TVdTz465msBYAj14tkiv8gGpyG62haIlxyJp5h62C0rcoXCy8z_JdSEeyI4G8gPvEhLvmudrysJHEU4UZERlZi7k3aSLF3sAWfrHuTxtl4Gl2JeVqA-pV2G_Yi4Az_VmbBWF4ATotbhbQut6CP4Fr3zMagvpRo2a49gGQ8g5q_Cnry4chkcnOL-CKbu9Fco4-e4SgVO6C9H2ViNglytAawIjaCUw9knWyguLB7XxYwTbttv_S7nmBSoGo3AaDdIAIYetvEZWmgsZITfSwteN0X88h_8UYl3YVx-4Pc4OwsvoZz-07Ps0nD28PPwxq6i4bI2f5ImoUNRrIrk20HpNZVR4fNN32NUdZQ7wOvDXoTUcXUauXPE1yVgvgIuq1193fkxxNg08gOOuONYTU_by6_MJM90Vd-yh-F5072xkD4tx6k6-BATaWGqfxGUc0JJZCpkagpXy1yQEl4r4szf0iM_kBXsRy8XMyUsWNQgNW705GNK1-fj5BBb6SYMoH_EokRiBJ4yIShqPwxwzs8qv2NsDZULrYRjfOiRB4UrgI8ST5mcagahXk8grREVC9qFIlk0ZwVWS1_imdi7ZIrDkEdFJ9Hd95UvAA-QkP4V2j9noVenCExupaBMgbtBt8FkOTqyXyDG_dsZ49OrHEGZ9RtcCUbKeNF4WSB7Yy9xGvduJCj8bQ-fcn-BFrz0y9pM3HaptMlN5Anb5w6coSJ5LVnzxqARDRWpBdkCxsxzbEJ8aROYC3B27daiM5l9MGEkIH9jXwA-5O0edGx8_BHNq6aosMSUN44lw3wQYyKoXkPqbk61IXv9ME | |
| dc.identifier.uri | https://hdl.handle.net/11424/291573 | |
| dc.identifier.volume | 37 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | NEPHROLOGY DIALYSIS TRANSPLANTATION | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Nefroloji | |
| dc.subject | Medicine | |
| dc.subject | Health Sciences | |
| dc.subject | Internal Medicine Sciences | |
| dc.subject | Internal Diseases | |
| dc.subject | Nephrology | |
| dc.subject | TRANSPLANTASYON | |
| dc.subject | Klinik Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | ÜROLOJİ VE NEFROLOJİ | |
| dc.subject | TRANSPLANTATION | |
| dc.subject | CLINICAL MEDICINE | |
| dc.subject | Clinical Medicine (MED) | |
| dc.subject | UROLOGY & NEPHROLOGY | |
| dc.subject | Üroloji | |
| dc.subject | Transplantasyon | |
| dc.subject | Urology | |
| dc.subject | Transplantation | |
| dc.title | Is there a relationship between fibroblast growth factor 23 and blood pressure in children with chronic kidney disease | |
| dc.type | article | |
| dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
